Protein Stability &
Expression Optimization

Protein stability is fundamentally about the free energy difference between the folded and unfolded states. A protein with a melting temperature (Tm) of 55°C may function in an assay but will not survive the thermal stresses of manufacturing, shipping, and long-term storage. For therapeutic antibodies, Tm values above 65–70°C are typically required to ensure adequate shelf life at 2–8°C. Nanobodies and single-domain antibodies often start with inherently high thermal stability due to their compact fold, but engineered variants can lose this advantage if mutations disrupt core packing or disulfide bonds.

Conformational stability goes beyond Tm. A protein may resist thermal unfolding yet still populate partially unfolded intermediates under physiological conditions—states that promote aggregation, chemical degradation, or loss of function. Differential scanning calorimetry (DSC), circular dichroism (CD), and hydrogen-deuterium exchange mass spectrometry (HDX-MS) provide complementary views of the conformational landscape. Computationally, molecular dynamics simulations and Rosetta-based energy calculations can predict which mutations stabilize the native state without requiring experimental screening of every variant.

Expression yield is one of the most practical determinants of a protein's viability as a therapeutic. The choice of expression system—E. coli for simple domains and fragments, HEK293 for rapid transient expression, CHO for stable production—depends on the molecule's size, glycosylation requirements, and disulfide bond complexity. Nanobodies and Fab fragments can often be produced in bacterial systems at high yield, while full-length IgGs require mammalian cells for proper folding and glycosylation.

Codon optimization tailors the DNA sequence to the host organism's translational machinery without changing the protein sequence. Beyond simple codon adaptation index (CAI) optimization, modern approaches consider mRNA secondary structure near the start codon, codon pair bias, and GC content uniformity to minimize ribosome stalling and premature termination. Signal peptide engineering—selecting or designing secretion signals matched to the host—can improve secreted yield by 2- to 10-fold in some systems.

Even a well-expressed, thermally stable protein can fail if it cannot be formulated for its intended route of administration. Buffer composition, pH, ionic strength, surfactant selection, and cryoprotectant choice all influence long-term stability. For high-concentration subcutaneous formulations, protein-protein interactions at 100+ mg/mL can cause opalescence, viscosity increases, and phase separation. These are intrinsic properties of the molecule's surface chemistry and are best addressed by engineering the protein itself—reducing surface hydrophobicity, redistributing charge patches, or introducing stabilizing mutations—rather than relying entirely on formulation excipients.